III期-话题@MedSci - williamhill asia

#III期#

681篇内容 | 3346人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594507, encodeId=9b33159450e08, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Arthritis Rheumatol：阿巴西普治疗多关节型幼年特发性关节炎的III期研究, objectType=article, longId=131452, objectId=61ff131452ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61ff131452ed, replyNumber=0, likeNumber=60, createdTime=2018-03-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61ff131452ed, moduleTitle=Arthritis Rheumatol：阿巴西普治疗多关节型幼年特发性关节炎的III期研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=61ff131452ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594506, encodeId=a3611594506f0, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=EUR J Cancer：一项比较SB3（曲妥珠单抗生物类似物）和曲妥珠单抗的III期临床研究, objectType=article, longId=130729, objectId=edaa130e2993, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edaa130e2993, replyNumber=0, likeNumber=56, createdTime=2018-02-28, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edaa130e2993, moduleTitle=EUR J Cancer：一项比较SB3（曲妥珠单抗生物类似物）和曲妥珠单抗的III期临床研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=edaa130e2993)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594505, encodeId=e6ee159450587, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Lancet：【重磅】III期研究显示肝癌治疗新药仑伐替尼有望成为一线治疗晚期肝癌标准, objectType=article, longId=129750, objectId=01d9129e5085, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01d9129e5085, replyNumber=0, likeNumber=72, createdTime=2018-02-14, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01d9129e5085, moduleTitle=Lancet：【重磅】III期研究显示肝癌治疗新药仑伐替尼有望成为一线治疗晚期肝癌标准, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=01d9129e5085)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594504, encodeId=57a61594504fe, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Teva的皮下哮喘药物在III期临床试验中失败, objectType=article, longId=127488, objectId=74dd12e488a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74dd12e488a0, replyNumber=0, likeNumber=53, createdTime=2018-01-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74dd12e488a0, moduleTitle=Teva的皮下哮喘药物在III期临床试验中失败, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=74dd12e488a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594503, encodeId=8ab51594503aa, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Brit J Cancer：II/III期结肠癌患者边侧性、分子亚型及治疗响应, objectType=article, longId=126567, objectId=c2d012656e30, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2d012656e30, replyNumber=0, likeNumber=56, createdTime=2018-01-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2d012656e30, moduleTitle=Brit J Cancer：II/III期结肠癌患者边侧性、分子亚型及治疗响应, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c2d012656e30)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594502, encodeId=58301594502e0, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=JAMA：idalopirdine治疗轻中度阿尔斯海默III期临床试验失败, objectType=article, longId=126123, objectId=8fa3126123fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fa3126123fa, replyNumber=0, likeNumber=37, createdTime=2018-01-12, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fa3126123fa, moduleTitle=JAMA：idalopirdine治疗轻中度阿尔斯海默III期临床试验失败, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=8fa3126123fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594501, encodeId=fd4b1594501ae, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Lancet：度鲁特韦联合利匹韦林治疗HIV-1型III期临床研究, objectType=article, longId=125930, objectId=85ca1259307a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85ca1259307a, replyNumber=0, likeNumber=58, createdTime=2018-01-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85ca1259307a, moduleTitle=Lancet：度鲁特韦联合利匹韦林治疗HIV-1型III期临床研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=85ca1259307a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594500, encodeId=b2471594500b7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Ann Rheum Dis：中日韩三国进行的贝利木单抗治疗系统性红斑狼疮的III期随机对照研究, objectType=article, longId=125389, objectId=931512538914, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=931512538914, replyNumber=0, likeNumber=61, createdTime=2018-01-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=931512538914, moduleTitle=Ann Rheum Dis：中日韩三国进行的贝利木单抗治疗系统性红斑狼疮的III期随机对照研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=931512538914)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594499, encodeId=0f351594499a9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=EUR J Cancer：聚乙二醇化脂质体多柔比星联合trebananib或安慰剂治疗卵巢癌的随机双盲III期临床试验, objectType=article, longId=125219, objectId=0ec912521937, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ec912521937, replyNumber=0, likeNumber=45, createdTime=2018-01-02, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ec912521937, moduleTitle=EUR J Cancer：聚乙二醇化脂质体多柔比星联合trebananib或安慰剂治疗卵巢癌的随机双盲III期临床试验, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0ec912521937)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594498, encodeId=2ad0159449822, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=EUR J Cancer：治疗结直肠癌患者的III期RECOURSE临床试验的亚组中 trifluridine / tipiracil（TAS-102）与安慰剂, objectType=article, longId=124746, objectId=df36124e4632, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df36124e4632, replyNumber=0, likeNumber=58, createdTime=2017-12-28, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df36124e4632, moduleTitle=EUR J Cancer：治疗结直肠癌患者的III期RECOURSE临床试验的亚组中 trifluridine / tipiracil（TAS-102）与安慰剂, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=df36124e4632)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594497, encodeId=b62a159449ea5, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Ann Rheum Dis： LBEC0101和依那西普对甲氨蝶呤反应不良性活动类风湿关节炎患者疗效和安全性的III期研究, objectType=article, longId=124092, objectId=25b012409255, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25b012409255, replyNumber=0, likeNumber=51, createdTime=2017-12-22, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25b012409255, moduleTitle=Ann Rheum Dis： LBEC0101和依那西普对甲氨蝶呤反应不良性活动类风湿关节炎患者疗效和安全性的III期研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=25b012409255)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594496, encodeId=4f24159449658, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Imbruvica®（依鲁替尼）联合利美罗华®（妥昔单抗）治疗罕见华氏巨球蛋白血症III期成功, objectType=article, longId=122645, objectId=70ef12264515, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70ef12264515, replyNumber=0, likeNumber=47, createdTime=2017-12-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70ef12264515, moduleTitle=Imbruvica®（依鲁替尼）联合利美罗华®（妥昔单抗）治疗罕见华氏巨球蛋白血症III期成功, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=70ef12264515)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594495, encodeId=5b2d159449514, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=JAMA Oncology：原发肿瘤位置对III期结肠癌预后有影响吗？, objectType=article, longId=122459, objectId=1b8512245933, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b8512245933, replyNumber=0, likeNumber=50, createdTime=2017-12-07, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b8512245933, moduleTitle=JAMA Oncology：原发肿瘤位置对III期结肠癌预后有影响吗？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1b8512245933)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594494, encodeId=ed8d159449411, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=诺华ACZ885在III期临床试验CANTOS受试者亚组中降低心血管风险25%, objectType=article, longId=120485, objectId=e3de120485e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3de120485e7, replyNumber=0, likeNumber=32, createdTime=2017-11-19, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3de120485e7, moduleTitle=诺华ACZ885在III期临床试验CANTOS受试者亚组中降低心血管风险25%, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e3de120485e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594493, encodeId=5c621594493d0, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NEJM：Durvalumab单抗治疗III期非小细胞肺癌, objectType=article, longId=120298, objectId=9c7d120298f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c7d120298f4, replyNumber=0, likeNumber=54, createdTime=2017-11-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c7d120298f4, moduleTitle=NEJM：Durvalumab单抗治疗III期非小细胞肺癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=9c7d120298f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594492, encodeId=185515944929b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NEJM：Dabrafenib联合Trametinib可显著降低III期BRAF V600突变黑色素瘤患者的术后复发风险, objectType=article, longId=119397, objectId=b09511939ebc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b09511939ebc, replyNumber=0, likeNumber=57, createdTime=2017-11-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b09511939ebc, moduleTitle=NEJM：Dabrafenib联合Trametinib可显著降低III期BRAF V600突变黑色素瘤患者的术后复发风险, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b09511939ebc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594491, encodeId=19dd1594491d7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NEJM：Nusinersen治疗婴儿脊髓性肌萎缩症III期临床结果, objectType=article, longId=118500, objectId=27dc1185009a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27dc1185009a, replyNumber=0, likeNumber=51, createdTime=2017-11-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27dc1185009a, moduleTitle=NEJM：Nusinersen治疗婴儿脊髓性肌萎缩症III期临床结果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=27dc1185009a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594490, encodeId=03a5159449094, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Lancet Neurol：依库珠单抗治疗抗乙酰胆碱受体抗体阳性难治性全身性重症肌无力III期临床研究, objectType=article, longId=117236, objectId=41dc11e236e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41dc11e236e9, replyNumber=0, likeNumber=43, createdTime=2017-10-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41dc11e236e9, moduleTitle=Lancet Neurol：依库珠单抗治疗抗乙酰胆碱受体抗体阳性难治性全身性重症肌无力III期临床研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=41dc11e236e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594489, encodeId=8d131594489a0, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=JAMA Oncology：DNA错配修复（MMR）状态能否预测III期结肠癌患者的预后？, objectType=article, longId=116304, objectId=d9c8116304cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9c8116304cc, replyNumber=0, likeNumber=54, createdTime=2017-10-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9c8116304cc, moduleTitle=JAMA Oncology：DNA错配修复（MMR）状态能否预测III期结肠癌患者的预后？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d9c8116304cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594488, encodeId=1433159448850, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NEJM：埃博拉疫苗III期临床研究, objectType=article, longId=115953, objectId=514d11595351, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=514d11595351, replyNumber=0, likeNumber=0, createdTime=2017-10-14, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=514d11595351, moduleTitle=NEJM：埃博拉疫苗III期临床研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=514d11595351)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Arthritis Rheumatol：阿巴西普治疗多关节型幼年特发性关节炎的III期研究

2018-03-06

智智灵药 (审核中...)

前往app查看评论内容

#III期#

EUR J Cancer：一项比较SB3（曲妥珠单抗生物类似物）和曲妥珠单抗的III期临床研究

2018-02-28

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Lancet：【重磅】III期研究显示肝癌治疗新药仑伐替尼有望成为一线治疗晚期肝癌标准

2018-02-14

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Teva的皮下哮喘药物在III期临床试验中失败

2018-01-25

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Brit J Cancer：II/III期结肠癌患者边侧性、分子亚型及治疗响应

2018-01-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

JAMA：idalopirdine治疗轻中度阿尔斯海默III期临床试验失败

2018-01-12

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Lancet：度鲁特韦联合利匹韦林治疗HIV-1型III期临床研究

2018-01-10

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Ann Rheum Dis：中日韩三国进行的贝利木单抗治疗系统性红斑狼疮的III期随机对照研究

2018-01-05

智智灵药 (审核中...)

前往app查看评论内容

#III期#

EUR J Cancer：聚乙二醇化脂质体多柔比星联合trebananib或安慰剂治疗卵巢癌的随机双盲III期临床试验

2018-01-02

智智灵药 (审核中...)

前往app查看评论内容

#III期#

EUR J Cancer：治疗结直肠癌患者的III期RECOURSE临床试验的亚组中 trifluridine / tipiracil（TAS-102）与安慰剂

2017-12-28

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Ann Rheum Dis： LBEC0101和依那西普对甲氨蝶呤反应不良性活动类风湿关节炎患者疗效和安全性的III期研究

2017-12-22

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Imbruvica®（依鲁替尼）联合利美罗华®（妥昔单抗）治疗罕见华氏巨球蛋白血症III期成功

2017-12-09

智智灵药 (审核中...)

前往app查看评论内容

#III期#

JAMA Oncology：原发肿瘤位置对III期结肠癌预后有影响吗？

2017-12-07

智智灵药 (审核中...)

前往app查看评论内容

#III期#

诺华ACZ885在III期临床试验CANTOS受试者亚组中降低心血管风险25%

2017-11-19

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NEJM：Durvalumab单抗治疗III期非小细胞肺癌

2017-11-18

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NEJM：Dabrafenib联合Trametinib可显著降低III期BRAF V600突变黑色素瘤患者的术后复发风险

2017-11-11

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NEJM：Nusinersen治疗婴儿脊髓性肌萎缩症III期临床结果

2017-11-04

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Lancet Neurol：依库珠单抗治疗抗乙酰胆碱受体抗体阳性难治性全身性重症肌无力III期临床研究

2017-10-25

智智灵药 (审核中...)

前往app查看评论内容

#III期#

JAMA Oncology：DNA错配修复（MMR）状态能否预测III期结肠癌患者的预后？

2017-10-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NEJM：埃博拉疫苗III期临床研究

2017-10-14

科室
- - 订阅+
  - 更多科室
工具
服务